Drug
ZD4054 clinical trials
Also written Zibotentan and ZD4054.
- studies test it
- 31
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
- ZD4054
- 13
Other names
Studies by the year they started
30 studies that test it; most in 2008 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 4 |
| 2010 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 16
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 9
AstraZeneca (22) · Cardiff University (2) · University Medical Center Groningen (1) · NHS Greater Glasgow and Clyde (1) · University College, London (1) · University of Virginia (1) · University of Wisconsin, Madison (1) · Aarhus University Hospital (1)
Often tested with
Tested in the same studies.
Dapagliflozin (6) · FOLFIRI Regimen (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1)
Studies
Open first, then newest update. How each study uses ZD4054 is read from its arms, and is right about nine times in ten.
Testing it · 31
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Active, not recruitingPhase 3AstraZenecaNCT06087835Written as Zibotentan/Dapagliflozin
- Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedPhase 2AstraZenecaNCT05516498Written as Part A: zibotentan (dose B) + dapagliflozin
- A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaActive, not recruitingPhase 2AstraZenecaNCT06942910Written as Zibotentan/Dapagliflozin
- A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without FoodCompletedPhase 1AstraZenecaNCT07404137Written as Zibotentan/Dapagliflozin FDC
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedPhase 2AstraZenecaNCT06269484Written as Zibotentan + dapagliflozin
- A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese ParticipantsCompletedPhase 1AstraZenecaNCT06715670Written as Zibotentan
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated AlbuminuriaCompletedPhase 2University Medical Center GroningenNCT05570305Written as Zibotentan
- Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)CompletedPhase 2AstraZenecaNCT04724837Written as Zibotentan
- Precision Medicine With Zibotentan in Microvascular AnginaCompletedPhase 2NHS Greater Glasgow and ClydeNCT04097314Written as Zibotentan
- Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.CompletedPhase 1AstraZenecaNCT05505162Written as Zibotentan
- A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal ImpairmentCompletedPhase 1AstraZenecaNCT05112419Written as Zibotentan
- ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate CancerTerminatedPhase 2University of Wisconsin, MadisonNCT01119118Written as ZD4054
- Carboplatin With or Without ZD4054 in Patients With Metastatic Breast CancerWithdrawnPhase 2Cardiff UniversityNCT01134497Written as ZD4054
- Zibotentan Better Renal Scleroderma Outcome StudyCompletedPhase 2University College, LondonNCT02047708Written as Zibotentan
- Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent ClaudicationCompletedPhase 2University of VirginiaNCT01890135Written as Zibotentan (ZD4054)
- A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesCompletedPhase 3AstraZenecaNCT00554229Written as ZD4054
- Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal CancerCompletedPhase 2Cardiff UniversityNCT01205711Written as zibotentan
- A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate CancerTerminatedPhase 2Aarhus University HospitalNCT01000948Written as ZD4054
- Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPCCompletedPhase 1AstraZenecaNCT00314782Written as ZD4054 (Zibotentan)
- ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)CompletedPhase 2AstraZenecaNCT00090363Written as ZD4054 15 mg
See all 31 studies that test ZD4054 →
Given in every arm · 2 — ZD4054 is usual care beside what is tested
- Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy ParticipantsCompletedPhase 1AstraZenecaNCT04991571Written as Zibotentan (Treatment A)
- Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc IntervalCompletedPhase 1AstraZenecaNCT00713336Written as ZD4054